Latest News Story Headlines
2025 Winter Newsletter
Be sure to catch up on the latest happenings in our winter newsletter.
Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema
January 22, 2025
Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
Nov 25, 2024
− Prescription Drug User Fee Act (PDUFA) Date Set for March 23, 2025 −
Calendar & Upcoming Events
Webinar: Mind Over Matter - Empower Your Healing Journey
Webinar Session, Wednesday, Jan. 22nd, 2025 at 6 PM (ET) Zoom Meeting
Webinar: Living Fully with Amyloidosis: A Roadmap to Fulfillment
Webinar Session, Wednesday, Jan. 29th, 2025 at 6 PM (ET) Zoom Meeting
Sign Up for the Latest Updates
Get news from Amyloidosis Foundation
in your inbox
By submitting this form, you are consenting to receive marketing emails from : Amyloidosis Foundation, 7151 N. Main St., Suite 2, Clarkston, MI, 48346, US, https://www.amyloidosis.org. You can revoke your consent to receive emails at any time by using SafeUnsubscribe© link, found at the bottom of every email. Emails are serviced by Constant Contract.